Glutamate dehydrogenase combined with ferrochelatase as a biomarker of liver injury induced by antituberculosis drugs

Abstract

AbstractAimsTo explore the potential value of serum glutamate dehydrogenase (GLDH), ferrochelatase (FECH), heme oxygenase‐1 (HO‐1) and glutathione‐S‐transferase‐α (GST‐α) as diagnostic biomarkers for liver injury caused by antituberculosis drugs.MethodsWe established a rat model of isoniazide‐induced liver injury and recruited 122 hospitalized tuberculosis patients taking antituberculosis drugs. We detected the concentration of GLDH, FECH, HO‐1 and GST‐α by enzyme‐linked immunosorbent assay. GraphPad Prism8 and SPSS 26.0 were used for statistical analysis.ResultsIn the rat model, serum GLDH concentration gradually increased during isoniazid (INH) administration, while serum FECH, HO‐1 and GST‐α concentrations significantly increased after INH administration was stopped. The receiver operating characteristic curve showed that the areas under the curve (AUCs) of serum GLDH and FECH for the diagnosis of anti‐tuberculosis (TB) drug‐induced liver injury (anti‐TB‐DILI) were 0.7692 (95% confidence interval [CI] 0.5442‐0.9943) and 0.7284 (95% CI 0.4863‐0.9705) and the diagnostic accuracies were 81.25% and 78.79%, respectively. In clinical research, the AUCs of GLDH and FECH were 0.9124 (95% CI 0.8380‐0.9867) and 0.6634 (95% CI 0.5391‐0.7877), and the optimal thresholds were 10.40 mIU/mL and 1.304 ng/mL, respectively. The diagnostic accuracy, specificity and positive predictive value (PPV) of GLDH were 82.61%, 79.38% and 47.22%. We performed a joint diagnostic test for GLDH and FECH. The diagnostic accuracy (90.43%), specificity (91.75%) and PPV (65.21%) of serial tests were better than for GLDH and FECH alone.ConclusionsGLDH in the diagnosis of liver injury induced by anti‐TB drugs has high sensitivity, but low specificity and low PPV. The combination of GLDH and FECH could significantly improve the specificity, PPV and diagnostic accuracy, and reduce the false‐positive rate of anti‐TB‐DILI.